Octylonium Bromide has been reported to antagonize PAF (platelet-activating factor) induced aggregation of rabbit platelet-rich plasma, hypotension in rats, lethality in mice, and bronchoconstriction in guinea-pigs. This compound also demonstrates the ability to potently block neuronal nicotinic acetylcholine receptors and also a mild wide-spectrum Ca2+ channel blocker in bovine adrenal chromaffin cells. Additionally, Octylonium Bromide has been shown to inhibit muscular action potentials carried by L-type Ca2+ current. Octylonium Bromide is an inhibitor of PAF-R.
1. Subissi, A., et al. 1989. Arch Int Pharmacodyn Ther. 302: 255-267. PMID: 2636821
2. Gandía, L., et al. 1996. Br. J. Pharmacol. 117: 463-470. PMID: 8821535
3. Martin, M.T., et al. 2004. Neurogastroenterol. Motil. 16: 175-183. PMID: 15086871
See how others have used Octylonium Bromide. Click on the entry to view the PubMed entry .
PMID: # 15086870 Strege, PR. et al. 2004. Neurogastroenterol. Motil. 16: 167-173.
PMID: # 9798806 Battaglia, G. et al. 1998. Aliment. Pharmacol. Ther. 12: 1003-1010.
PMID: # 3168757 Manzini, S. et al. 1988. Drugs Exp Clin Res. 14: 265-270.
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.